MEN2B
MCID: MLT025
MIFTS: 56

Multiple Endocrine Neoplasia Iib (MEN2B) malady

Categories: Genetic diseases, Rare diseases, Gastrointestinal diseases, Endocrine diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Multiple Endocrine Neoplasia Iib

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 24GeneTests, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Multiple Endocrine Neoplasia Iib:

Name: Multiple Endocrine Neoplasia Iib 52 12
Multiple Endocrine Neoplasia Type 2b 11 48 24 54 27 39 13 68
Men2b 11 24 54 70
Wagenmann-Froboese Syndrome 11 48 54
Mucosal Neuroma Syndrome 11 48 24
Men 2b 48 24
 
Multiple Endocrine Neoplasia, Type Iib 52
Multiple Endocrine Neoplasia, Type 3 11
Multiple Endocrine Neoplasia Type 3 54
Multiple Neoplasia 2b 70
Men Type Iib 11

Characteristics:

Orphanet epidemiological data:

54
multiple endocrine neoplasia type 2b:
Inheritance: Autosomal dominant; Age of onset: Childhood

HPO:

64
multiple endocrine neoplasia iib:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM52 162300
Disease Ontology11 DOID:10016
ICD1030 E31.23
ICD9CM32 258.03
MeSH39 D018814
NCIt45 C3227
SNOMED-CT62 61530001
Orphanet54 ORPHA247709
MESH via Orphanet40 D018814
ICD10 via Orphanet31 D44.8
UMLS via Orphanet69 C0025269
MedGen37 C0025269

Summaries for Multiple Endocrine Neoplasia Iib

About this section
OMIM:52 Multiple endocrine neoplasia type IIB (MEN2B) is an autosomal dominant hamartoneoplastic syndrome characterized by... (162300) more...

MalaCards based summary: Multiple Endocrine Neoplasia Iib, also known as multiple endocrine neoplasia type 2b, is related to pheochromocytoma and medullary thyroid carcinoma, familial, and has symptoms including constipation, constipation and diarrhea. An important gene associated with Multiple Endocrine Neoplasia Iib is RET (Ret Proto-Oncogene), and among its related pathways are Endothelin Pathways and NCAM1 interactions. Affiliated tissues include thyroid, colon and skin, and related mouse phenotypes are endocrine/exocrine gland and muscle.

Disease Ontology:11 An autosomal dominant disease characterized by medullary thyroid carcinoma, pheochromocytoma, multiple mucosal neuromas and intestinal ganglioneuromas, and often a marfanoid habitus and other skeletal abnormalities.

UniProtKB/Swiss-Prot:70 Multiple neoplasia 2B: Uncommon inherited cancer syndrome characterized by predisposition to MTC and phaeochromocytoma which is associated with marfanoid habitus, mucosal neuromas, skeletal and ophthalmic abnormalities, and ganglioneuromas of the intestine tract. Then the disease progresses rapidly with the development of metastatic MTC and a pheochromocytome in 50% of cases.

Related Diseases for Multiple Endocrine Neoplasia Iib

About this section

Diseases in the Multiple Endocrine Neoplasia family:

Multiple Endocrine Neoplasia Iia multiple endocrine neoplasia iib
Multiple Endocrine Neoplasia 1 Multiple Endocrine Neoplasia, Type Iv

Diseases related to Multiple Endocrine Neoplasia Iib via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 60)
idRelated DiseaseScoreTop Affiliating Genes
1pheochromocytoma29.8CALCA, GDNF, MEN1, RET
2medullary thyroid carcinoma, familial10.8
3multiple endocrine neoplasia iia10.8
4multiple endocrine neoplasia 110.8
5gastrinoma10.3CALCA, RET
6meigel disease10.2GDNF, RET
7pemphigus foliaceus10.2CALCA, MEN1
8waardenburg syndrome, type 4a10.2EDNRB, RET
9paranasal sinus cancer, adult10.2CALCA, MEN1
10hyperparathyroidism, familial primary10.2MEN1, RET
11adult ependymoblastoma10.2CALCA, MEN1
12early-onset parkinson disease10.2MEN1, RET
13hypoparathyroidism-intellectual disability-dysmorphism syndrome10.2GDNF, RET
14ceroid lipofuscinosis, neuronal, 510.2EDNRB, RET
15immunodeficiency by defective expression of hla class 110.2CALCA, EDNRB
16gemistocytic astrocytoma10.2CALCA, MEN1
17multiple endocrine neoplasia10.2
18hereditary persistence of fetal hemoglobin-beta-thalassemia syndrome10.2OSMR, RET
19acute cor pulmonale10.2CALCA, EDNRB
20cardioauditory syndrome of sanchez cascos10.2CALCA, MEN1
21apocrine adenoma10.2EDNRB, RET
22keloids10.2CALCA, MEN1
23epidermolysis bullosa, junctional, herlitz type10.2CALCA, MEN1
24hemopericardium10.2CALCA, EDNRB
25nodular prostate10.2CALCA, RET
26infertility10.2PTCH1, RET
27cowden syndrome 310.2CALCA, MEN1, RET
28opioid abuse10.2CALCA, MEN1, RET
29parathyroid carcinoma10.1CALCA, MEN1, RET
30gastroduodenal crohn's disease10.1GDNF, GFRA1
31cowper gland carcinoma10.1MEN1, RET
32subserous uterine fibroid10.1CALCA, MEN1, RET
33connective tissue cancer10.1CALCA, GDNF, RET
34endocrine gland cancer10.1CALCA, MEN1, RET
35shprintzen-goldberg syndrome10.1EDNRB, GDNF, RET
36ariboflavinosis10.1EDNRB, GDNF, RET
37mucositis10.1
38neuroma10.1
39spinal meningioma10.1EDNRB, GDNF, RET
40isolated methylmalonic acidemia10.1GDNF, RET
41t-cell adult acute lymphocytic leukemia10.1PTCH1, RET
42chronic infections, due to mbl deficiency10.1EDNRB, GDNF, RET
43sweat gland cancer10.1EDNRB, GDNF, RET
44corneal ulcer10.1CALCA, GDNF
45vestibulocochlear nerve disease10.1GDNF, RET
46t-cell large granular lymphocyte leukemia10.1MEN1, PTCH1, RET
47multiple mucosal neuroma10.0
48aneurysm10.0CALCA, GDNF, MEN1, RET
49urinary tract papillary transitional cell benign neoplasm10.0CALCA, RET
50benign shuddering attacks10.0CALCA, MEN1, PTCH1, RET

Graphical network of the top 20 diseases related to Multiple Endocrine Neoplasia Iib:



Diseases related to multiple endocrine neoplasia iib

Symptoms & Phenotypes for Multiple Endocrine Neoplasia Iib

About this section

Symptoms by clinical synopsis from OMIM:

162300

Clinical features from OMIM:

162300

Human phenotypes related to Multiple Endocrine Neoplasia Iib:

 64 (show all 27)
id Description HPO Frequency HPO Source Accession
1 thick lower lip vermilion64 HP:0000179
2 thick eyebrow64 HP:0000574
3 pectus excavatum64 HP:0000767
4 abnormality of the skin64 HP:0000951
5 muscular hypotonia64 HP:0001252
6 global developmental delay64 HP:0001263
7 joint laxity64 HP:0001388
8 disproportionate tall stature64 HP:0001519
9 failure to thrive in infancy64 HP:0001531
10 pes cavus64 HP:0001761
11 diarrhea64 HP:0002014
12 constipation64 HP:0002019
13 aganglionic megacolon64 HP:0002251
14 colonic diverticula64 HP:0002253
15 scoliosis64 HP:0002650
16 pheochromocytoma64 HP:0002666
17 high, narrow palate64 HP:0002705
18 kyphosis64 HP:0002808
19 medullary thyroid carcinoma64 HP:0002865
20 ganglioneuroma64 HP:0003005
21 myopathy64 HP:0003198
22 hyperlordosis64 HP:0003307
23 elevated calcitonin64 HP:0003528
24 elevated urinary epinephrine64 HP:0003639
25 nodular goiter64 HP:0005994
26 proximal femoral epiphysiolysis64 HP:0006461
27 parathyroid hyperplasia64 HP:0008208

UMLS symptoms related to Multiple Endocrine Neoplasia Iib:


constipation, diarrhea, joint laxity

MGI Mouse Phenotypes related to Multiple Endocrine Neoplasia Iib according to GeneCards Suite gene sharing:

41 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053798.9EDNRB, GDNF, MEN1, OSMR, PTCH1, RET
2MP:00053698.9EDNRB, GDNF, GFRA1, MEN1, PTCH1, RET
3MP:00053808.7EDNRB, GFRA1, MEN1, NCK1, PTCH1, RET
4MP:00053878.4EDNRB, GDNF, GFRA1, MEN1, OSMR, PTCH1
5MP:00053848.3EDNRB, GDNF, GFRA1, MEN1, NCK1, PTCH1
6MP:00036318.2EDNRB, GDNF, GFRA1, MEN1, NCK1, PTCH1
7MP:00053818.1EDNRB, GDNF, GFRA1, MEN1, PTCH1, RET
8MP:00053677.8EDNRB, GDNF, GFRA1, NCK1, PTCH1, RET
9MP:00107687.4EDNRB, GDNF, GFRA1, MEN1, NCK1, PTCH1
10MP:00053787.4EDNRB, GDNF, MEN1, NCK1, OSMR, PTCH1
11MP:00053867.3EDNRB, GDNF, GFRA1, NCK1, OSMR, PTCH1

Drugs & Therapeutics for Multiple Endocrine Neoplasia Iib

About this section

Drugs for Multiple Endocrine Neoplasia Iib (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 111)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Bevacizumabapproved, investigationalPhase 32020216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
2
CarboplatinapprovedPhase 3205041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
3
Paclitaxelapproved, vet_approvedPhase 3286433069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
4
Oxaliplatinapproved, investigationalPhase 3146061825-94-35310940, 9887054, 6857599, 9887054, 43805
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
5
FluorouracilapprovedPhase 3, Phase 2185651-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
6
LevoleucovorinapprovedPhase 3, Phase 272868538-85-2
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-formyltetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
 
(S)-Leucovorin
Citrovorum factor
L-Folinic acid
Levofolene
Levofolinic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
7
GemcitabineapprovedPhase 3, Phase 2, Phase 1201895058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
8
leucovorinapproved, NutraceuticalPhase 3, Phase 2, Phase 1323558-05-954575, 6560146, 143
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formyltetrahydrofolic acid
Acide folinique
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinate
Folinic acid
Folinic acid calcium salt
 
Folinic acid calcium salt USP27
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
L-Leucovorin
L-N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-Glutamic acid
L-leucovorin
Leucal
Leucovorin calcium
Leucovorin folinic acid
Leucovorinum
Leukovorin
Levoleucovorin
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyl-THF
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Welcovorin
Wellcovorin
folinate
9
Folic Acidapproved, nutraceutical, vet_approvedPhase 3, Phase 2, Phase 1439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
10Albumin-Bound PaclitaxelPhase 32864
11Angiogenesis Modulating AgentsPhase 34185
12Angiogenesis InhibitorsPhase 34257
13Antimitotic AgentsPhase 35657
14Antineoplastic Agents, PhytogenicPhase 3, Phase 25602
15Trace ElementsPhase 3, Phase 2, Phase 16001
16VitaminsPhase 3, Phase 2, Phase 15282
17Vitamin B ComplexPhase 3, Phase 2, Phase 14337
18MicronutrientsPhase 3, Phase 2, Phase 16001
19Protective AgentsPhase 3, Phase 27443
20Immunosuppressive AgentsPhase 3, Phase 2, Phase 113086
21Anti-Infective AgentsPhase 3, Phase 1, Phase 222062
22AntidotesPhase 3, Phase 21071
23Antimetabolites, AntineoplasticPhase 3, Phase 2, Phase 17361
24AntimetabolitesPhase 3, Phase 2, Phase 112054
25Antiviral AgentsPhase 3, Phase 1, Phase 29967
26HematinicsPhase 3, Phase 2, Phase 11684
27FolateNutraceuticalPhase 3, Phase 2, Phase 14392
28Vitamin B9NutraceuticalPhase 3, Phase 2, Phase 14392
29
Topotecanapproved, investigationalPhase 2349119413-54-6, 123948-87-860700
Synonyms:
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione
(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
123948-87-8
9-Dimethylaminomethyl-10-hydroxycamptothecin
9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin
AC-11592
AC1L1TQZ
AC1Q6APZ
BSPBio_002348
C11158
C23H23N3O5
CCRIS 8163
CHEBI:107501
CHEBI:46035
CHEMBL84
CID60700
D08618
DB01030
HMS2090B20
HSCI1_000228
Hycamptamine
Hycamptin
Hycamtamine
Hycamtin
Hycamtin (TN)
LS-127395
 
MLS000759456
NCGC00178695-01
NCI60_004771
NCIStruc1_001659
NCIStruc2_001796
NChemBio.2007.10-comp24
NSC609699
SK&F-104864-A
SKF 104864
SKF-104864-A
SKF-S 104864
SMP2_000312
SMP2_000327
SMR000466344
TOPO
TOPOTECAN, HYCAMTIN
TPT
TTC
Topotecan (BAN)
Topotecan Hcl
Topotecan Hydrochloride
Topotecan Lactone
Topotecan Monohydrochloride, (S)-Isomer
Topotecan [INN:BAN]
Topotecan lactone
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
UNII-7M7YKX2N15
topotecan
30
Testosteroneapproved, investigationalPhase 256358-22-06013
Synonyms:
(+)-testosterone
(+-)-8-iso-testosterone
(+-)-retrotestosterone
(+-)-testosterone
(17b)-17-hydroxy-androst-4-en-3-one
(17beta)-17-Hydroxyandrost-4-en-3-one
(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
13-Iso-testosterone
17-Hydroxy-(17-beta)-androst-4-en-3-one
17-Hydroxy-(17beta)-androst-4-en-3-one
17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one
17-Hydroxy-D4-androsten-3-one
17-Hydroxy-androst-4-en-3-one
17-beta-Hydroxy-delta(sup 4)-androsten-3-one
17-beta-Hydroxyandrost-4-en-3-one
17?-Hydroxy-4-androsten-3-one
17a-Hydroxy-(13a)-androst-4-en-3-one
17a-Hydroxy-13a-androst-4-en-3-one
17a-Hydroxy-14b-androst-4-en-3-one
17a-Hydroxy-androst-4-en-3-one
17b-Hydroxy-(10a)-androst-4-en-3-one
17b-Hydroxy-(13a)-androst-4-en-3-one
17b-Hydroxy-(8a)-androst-4-en-3-one
17b-Hydroxy-(8a,10a)-androst-4-en-3-one
17b-Hydroxy-(9b)-androst-4-en-3-one
17b-Hydroxy-(9b,10a)-androst-4-en-3-one
17b-Hydroxy-13a-androst-4-en-3-one
17b-Hydroxy-8a-androst-4-en-3-one
17b-Hydroxy-D4-androsten-3-one
17b-Hydroxy-androst-4-en-3-on
17b-Hydroxy-androst-4-en-3-one
17b-Hydroxyandrost-4-en-3-one
17b-Hydroxyandrost-4-ene-3-one
17b-Testosterone
17b-hydroxy-4-androsten-3-one
17beta-Hydroxy-3-oxo-4-androstene
17beta-Hydroxy-4-androsten-3-one
17beta-Hydroxy-delta(sup4)-androsten-3-one
17beta-Hydroxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-ene-3-one
17beta-hydroxy-4-androsten-3-one
4-Androsten-17?-ol-3-one
4-Androsten-17beta-ol-3-one
4-Androsten-3-one-17b-ol
4-androsten-17β-ol-3-one
4-androstene-17beta-ol-3-one
46923_FLUKA
46923_RIEDEL
58-22-0
7-beta-Hydroxyandrost-4-en-3-one
8-Iso-testosterone
9b,10a-Testosterone
9b-Testosterone
AA 2500
AC-14899
AC1L1LM0
Andriol
Andro
Andro 100
Andro L.A. 200
AndroGel
Androderm
Androderm (TN)
Androgel
Androgel (TN)
Android 10
Android 25
Android 5
Androlin
Andronaq
Andronate 100
Andronate 200
Andropatch
Andropository 200
Androsorb
Androst-4-en-17b-ol-3-one
Androst-4-en-17beta-ol-3-one
Androst-4-ene-17b-ol-3-one
Andrusol
Andryl 200
B5DEE83F-632B-48A1-A0ED-A51E7F13DF2E
BIDD:ER0555
BIM-0061761.0001
Beta Testosterone
Bio-0678
Bio-T-Gel
C00535
CCRIS 574
CDB 111C
CHEBI:17347
CHEMBL386630
CID6013
CMC_13449
COL 1621
CP 601B
CPD000058344
Cristerona T
Cristerone T
D00075
D4-Androsten-17b-ol-3-one
DB00624
Dea No. 4000
Delatest
Delatestryl
Depo-Testadiol
Depo-Testosterone
Depo-Testosterone Cypionate
Depotest
EINECS 200-370-5
Epitestosteron
Everone 200
Geno-Cristaux Gremy
Geno-cristaux Gremy
Geno-cristaux gremy
HMS2052N11
HSDB 3398
Halotensin
Homosteron
Homosterone
 
Intrinsa
LMST02020002
LS-148813
LibiGel
Libigel
Lumitestosteron
MLS000563091
MLS001032098
MLS001306401
MLS002174283
Malerone
Malestrone
Malestrone (amps)
Malogen in Oil
Malogen, Aquaspension Injection
Malogen, aquaspension injection
Mertestate
Metandren
Methyltestosterone
MolPort-002-506-901
NCGC00091018-01
NSC 9700
Neo-Hombreol F
Neo-Testis
Neo-testis
Neotestis
Oreton
Oreton F
Oreton Methyl
Oreton-F
Orquisteron
Perandren
Percutacrine Androgenique
Percutacrine androgenique
Primotest
Primoteston
Rac-17b-hydroxy-(13a)androst-4-en-3-one
Rac-17b-hydroxy-(8a)-androst-4-en-3-one
Rac-17b-hydroxy-(9b,10a)androst-4-en-3-one
Rac-17b-hydroxy-androst-4-en-3-one
Relibra
Retrotestosterone
S00309
S2033_Selleck
SAM001246921
SMR000058344
SMR001261453
Scheinpharm Testone-Cyp
Striant
Striant (TN)
Sustanon
Sustanone
Sustason 250
Synandrol F
T-Cypionate
T1500_SIGMA
T5411_FLUKA
T5411_SIGMA
TES
Teslen
Testamone 100
Testandrone
Testaqua
Testiculosterone
Testim
Testim (TN)
Testobase
Testoderm
Testoderm Tts
Testogel
Testoject-50
Testolent
Testolin
Testopel Pellets
Testopropon
Testosteroid
Testosteron
Testosterona
Testosterona [INN-Spanish]
Testosterone
Testosterone (JAN/USP)
Testosterone Cypionate
Testosterone Enanthate
Testosterone Hydrate
Testosterone [Androgenic steroids, anabolic]
Testosterone [INN:BAN]
Testosterone and its esters
Testosterone hydrate
Testosterone solution
Testosteronum
Testosteronum [INN-Latin]
Testostosterone
Testostérone
Testoviron
Testoviron Schering
Testoviron T
Testoxyl
Testred
Testred Cypionate 200
Testrin-P.A
Testro AQ
Testro Aq
Testrone
Testryl
Tostrelle
Tostrex
Trans-Testosterone
UNII-3XMK78S47O
Viatrel
Virilon
Virilon IM
Virormone
Virosterone
ZINC06500184
beta testosterone
delta(sup 4)-Androsten-17(beta)-ol-3-one
delta4-Androsten-17beta-ol-3-one
delta4-androsten-17b-ol-3-one
testosterone
trans-Testosterone
31
Bortezomibapproved, investigationalPhase 1, Phase 2807179324-69-7387447, 93860
Synonyms:
179324-69-7
AC1L8TUW
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP-341
LDP341
LPD 341
LPD-341
 
MLN341
MolPort-003-845-298
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
NCI60_029010
NSC-681239
NSC681239
PROSCRIPT BORONIC ACID
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
bortezomib
32
MethyltestosteroneapprovedPhase 256358-18-46010
Synonyms:
17(alpha)-Methyl-delta(4)-androsten-17(beta)-ol-3-one
17-Methyltestosterone
17-beta-Hydroxy-17-methylandrost-4-en-3-one
17-methyltestosterone
17alpha-Methyl-3-oxo-4-androsten-17beta-ol
17alpha-Methyl-delta(4)-androsten-17beta-ol-3-one
17alpha-Methyltestosterone
17alpha-methyl-delta-androsten-17beta-ol-3-one
17alpha-methyltestosterone
 
17beta-Hydroxy-17-methylandrost-4-en-3-one
17α-methyl-Δ4-androsten-17β-ol-3-one
17α-methyltestosterone
4-Androstene-17alpha-methyl-17beta-ol-3-one
Android
Methyltestosterone
Methyltestosteronum
Metiltestosterona
NSC-9701
Testred
Virilon
33
OlaparibapprovedPhase 2140763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
34
Zoledronic acidapprovedPhase 2294118072-93-868740
Synonyms:
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate
(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
118072-93-8
2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
AC-1092
AC1L2ACJ
AC1Q6RN3
AKOS005145739
Aclasta
Anhydrous Zoledronic Acid
BIDD:GT0292
BIDD:PXR0134
Bio-0112
Bisphosphonate 3
C088658
CGP 42'446
CGP 42446
CGP 42446A
CGP-42'446
CGP-42446
CHEBI:46557
CHEMBL924
CID68740
D08689
DB00399
 
FT-0082657
HMS2089O09
I06-0710
KS-1132
LS-181815
MolPort-002-885-874
MolPort-003-850-890
NCGC00159521-02
NCGC00159521-03
NSC721517
Novartis brand of zoledronic acid
Reclast
Reclast (TN)
S00092
S1314_Selleck
UNII-70HZ18PH24
ZOL
Zol
Zoledronate
Zoledronic Acid Anhydrous
Zoledronic Acid, Anhydrous
Zoledronic acid
Zoledronic acid (INN)
Zoledronic acid [USAN:INN]
Zometa
Zometa (Novartis)
Zometa (TN)
Zometa Concentrate
Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
35
NelfinavirapprovedPhase 2139159989-64-764143
Synonyms:
(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide
(3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide
159989-64-7
159989-65-8 (monomethane sulfonate (salt))
1UN
1ohr
2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE
AC-20032
AC1L20J6
AG 1343
AG1343
AG1343 (*Mesylate salt*)
AG1346
AKOS000280862
BIDD:GT0395
BIDD:PXR0143
C07257
C32H45N3O4S
CHEMBL584
CID64143
D08259
DB00220
LS-85417
MLS001195634
 
MLS001304729
Met-SDF-1.beta. & Nelfinavir
Met-Stromal Cell-derived Factor-1.beta. (Human) & Nelfinavir
MolPort-000-883-833
MolPort-002-885-844
NCGC00090782-03
NCGC00090782-04
NELFINAVIR MESYLATE AG1343
NFV
NLF
NSC722664
NSC747167
Nelfinavir
Nelfinavir (INN)
Nelfinavir Monomethane Sulfonate
Nelfinavir [BAN:INN]
Nelfinavir [INN:BAN]
Nelfinavir mesylate
SMR000596515
UNII-HO3OGH5D7I
VRX496
Viracept
Viracept (TM)(*Mesylate salt*)
Viracept (TN)
ag1343
nelfinavir
36
Capecitabineapproved, investigationalPhase 2, Phase 11342154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
37
CamptothecinexperimentalPhase 27147689-03-4
Synonyms:
(+)-camptothecin
(+)-camptothecine
(s)-(+)-camptothecin
 
(s)-camptothecin
20(S)-Camptothecin
21,22-Secocamptothecin-21-oic acid lactone
Camptothecine
D-camptothecin
38
EnclomipheneinvestigationalPhase 216715690-57-0
Synonyms:
Enclomifeno
 
Enclomifenum
trans-Clomifene
trans-Clomiphene
39
CediranibinvestigationalPhase 293288383-20-09933475
Synonyms:
288383-20-0
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
790713-41-6
AKOS005145767
AZD 2171
AZD-2171
AZD2171
AZD2171, Recentin, Cediranib
CHEMBL491473
CID9933475
 
Cediranib
Cediranib (USAN/INN)
Cediranib maleate
D08881
EC-000.2328
Kinome_3318
M6294
NSC-732208
Recentin
S1017_Selleck
UNII-NQU9IPY4K9
ZD-2171
cediranib
40Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 213168
41HormonesPhase 214415
42Hormone AntagonistsPhase 213180
43Testosterone 17 beta-cypionatePhase 2563
44ZuclomiphenePhase 2167
45Testosterone undecanoatePhase 2563
46Selective Estrogen Receptor ModulatorsPhase 2601
47Fertility AgentsPhase 2505
48
Testosterone enanthatePhase 2563315-37-79416
Synonyms:
17-((1-Oxoheptyl)oxy)androst-4-en-3-one
17-Hydroxyandrost-4-en-3-one, 17-heptanoate
17-Hydroxyandrost-4-en-3-one, 17-heptanoic acid
17beta-Enanthoxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-en-3-one enanthate
4-Androsten-17beta-ol-3-one 17-enanthate
4-Androsten-3-one 17beta-enanthate
Androgyn L.A.
Andropository
Androtardyl
Atlatest
DEA No. 4000
DePatestrye
Delatest
Delatestryl
Depo-Testro Med
Ditate
Durathate
Everone
 
Exten test
Malogen L.A.
Malogen L.A.200
Orquisteron-E
Primotestone
Reposo TMD
Testanthate
Testate
Testenate
Testinon
Testoenant
Testonenant
Testosterone 17-enanthate
Testosterone 17beta-heptanoate
Testosterone 17beta-heptanoic acid
Testosterone enantate
Testosterone heptoate
Testosterone heptoic acid
Testosterone heptylate
Testosterone oenanthate
Testostroval
49BelotecanPhase 28
50Topoisomerase InhibitorsPhase 2, Phase 15069

Interventional clinical trials:

(show all 20)
idNameStatusNCT IDPhase
1Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity CancerCompletedNCT00483782Phase 3
2Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative ResectionRecruitingNCT02506842Phase 3
3A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)CompletedNCT00923247Phase 1, Phase 2
4Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb TrialCompletedNCT01630018Phase 2
5Normalization of Morning Testosterone Levels in Men With Secondary HypogonadismCompletedNCT01270841Phase 2
6To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical TestosteroneCompletedNCT00706719Phase 2
7DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in RemissionRecruitingNCT02166905Phase 1, Phase 2
8Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian CancerRecruitingNCT02889900Phase 2
9Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine With or Without Zoledronic Acid in Treating Patients With Locally Advanced Pancreatic CancerRecruitingNCT03073785Phase 2
10Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic CancerRecruitingNCT01959672Phase 2
11Vandetanib to Treat Children and Adolescents With Medullary Thyroid CancerActive, not recruitingNCT00514046Phase 1, Phase 2
12Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid TumorsCompletedNCT02262455Phase 1
13Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation With Gemcitabine, Sorafenib and Vorinostat in Resectable, Borderline Resectable or Unresectable Non-metastatic Pancreas CancerRecruitingNCT02349867Phase 1
14Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT01606241Phase 1
15Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorNot yet recruitingNCT02831179Phase 1
16Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals PatientsCompletedNCT01424878
17Natural History Study of Children and Young Adults With Medullary Thyroid CancerRecruitingNCT01660984
18Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based ChemotherapyRecruitingNCT02414100
19Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients With Gastrointestinal Cancer Undergoing SurgeryActive, not recruitingNCT02511821
20An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)Enrolling by invitationNCT01511393

Search NIH Clinical Center for Multiple Endocrine Neoplasia Iib


Cochrane evidence based reviews: multiple endocrine neoplasia type 2b

Genetic Tests for Multiple Endocrine Neoplasia Iib

About this section

Genetic tests related to Multiple Endocrine Neoplasia Iib:

id Genetic test Affiliating Genes
1 Multiple Endocrine Neoplasia, Type 2b27
2 Multiple Endocrine Neoplasia Type 2b24

Anatomical Context for Multiple Endocrine Neoplasia Iib

About this section

MalaCards organs/tissues related to Multiple Endocrine Neoplasia Iib:

36
Thyroid, Colon, Skin, Prostate

Publications for Multiple Endocrine Neoplasia Iib

About this section

Articles related to Multiple Endocrine Neoplasia Iib:

idTitleAuthorsYear
1
Cutaneous metastasis of pheochromocytoma in multiple endocrine neoplasia IIB. (16844526)
2006
2
The significance of cystic adrenal lesions in multiple endocrine neoplasia IIB syndrome. (15455172)
2004
3
Primary carcinoid of the prostate in conjunction with multiple endocrine neoplasia IIb in a child. (7853568)
1995
4
Multiple endocrine neoplasia IIb: an unusual cause of chronic constipation. (1967640)
1990
5
Early total thyroidectomy in patients with multiple endocrine neoplasia IIb syndrome. (2573160)
1989

Variations for Multiple Endocrine Neoplasia Iib

About this section

UniProtKB/Swiss-Prot genetic disease variations for Multiple Endocrine Neoplasia Iib:

70
id Symbol AA change Variation ID SNP ID
1RETp.Met918ThrVAR_006342rs74799832
2RETp.Thr946MetVAR_006345
3RETp.Ala883PheVAR_009485rs377767429

Clinvar genetic disease variations for Multiple Endocrine Neoplasia Iib:

5 (show all 16)
id Gene Variation Type Significance SNP ID Assembly Location
1RETNM_ 020975.4(RET): c.1901G> A (p.Cys634Tyr)SNVPathogenic/ Likely pathogenicrs75996173GRCh37Chr 10, 43609949: 43609949
2RETNM_ 020630.4(RET): c.1859G> A (p.Cys620Tyr)SNVPathogenic/ Likely pathogenicrs77503355GRCh37Chr 10, 43609103: 43609103
3RETNM_ 020975.4(RET): c.1900T> C (p.Cys634Arg)SNVPathogenic/ Likely pathogenicrs75076352GRCh37Chr 10, 43609948: 43609948
4RETNM_ 020630.4(RET): c.1902C> G (p.Cys634Trp)SNVPathogenic/ Likely pathogenicrs77709286GRCh37Chr 10, 43609950: 43609950
5RETNM_ 020975.4(RET): c.2753T> C (p.Met918Thr)SNVPathogenic/ Likely pathogenicrs74799832GRCh37Chr 10, 43617416: 43617416
6RETNM_ 020630.4(RET): c.1859G> T (p.Cys620Phe)SNVPathogenicrs77503355GRCh37Chr 10, 43609103: 43609103
7RETNM_ 020630.4(RET): c.1852T> C (p.Cys618Arg)SNVPathogenic/ Likely pathogenicrs76262710GRCh37Chr 10, 43609096: 43609096
8RETNM_ 020630.4(RET): c.2304G> C (p.Glu768Asp)SNVPathogenic/ Likely pathogenicrs78014899GRCh37Chr 10, 43613840: 43613840
9RETNM_ 020975.4(RET): c.1826G> A (p.Cys609Tyr)SNVPathogenic/ Likely pathogenicrs77939446GRCh37Chr 10, 43609070: 43609070
10RETNM_ 020975.4(RET): c.2671T> G (p.Ser891Ala)SNVPathogenic/ Likely pathogenicrs75234356GRCh37Chr 10, 43615592: 43615592
11RETNM_ 020975.4(RET): c.1853G> A (p.Cys618Tyr)SNVPathogenic/ Likely pathogenicrs79781594GRCh37Chr 10, 43609097: 43609097
12RETNM_ 020630.4(RET): c.1888T> C (p.Cys630Arg)SNVPathogenic/ Likely pathogenicrs377767404GRCh37Chr 10, 43609936: 43609936
13RETNM_ 020975.4(RET): c.2410G> A (p.Val804Met)SNVPathogenicrs79658334GRCh37Chr 10, 43614996: 43614996
14RETNM_ 020630.4(RET): c.2304G> T (p.Glu768Asp)SNVPathogenic/ Likely pathogenicrs78014899GRCh37Chr 10, 43613840: 43613840
15RETNM_ 020630.4(RET): c.2410G> C (p.Val804Leu)SNVPathogenic/ Likely pathogenicrs79658334GRCh37Chr 10, 43614996: 43614996
16RETNM_ 020975.4(RET): c.2647_ 2648delGCinsTT (p.Ala883Phe)indelPathogenic/ Likely pathogenicrs377767429GRCh37Chr 10, 43615568: 43615569

Expression for genes affiliated with Multiple Endocrine Neoplasia Iib

About this section
Search GEO for disease gene expression data for Multiple Endocrine Neoplasia Iib.

Pathways for genes affiliated with Multiple Endocrine Neoplasia Iib

About this section

GO Terms for genes affiliated with Multiple Endocrine Neoplasia Iib

About this section

Biological processes related to Multiple Endocrine Neoplasia Iib according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of osteoblast differentiationGO:004566810.3MEN1, PTCH1
2branching involved in ureteric bud morphogenesisGO:000165810.3GDNF, PTCH1
3posterior midgut developmentGO:000749710.3EDNRB, RET
4peripheral nervous system developmentGO:000742210.2EDNRB, GDNF
5ureteric bud developmentGO:000165710.2GDNF, RET
6enteric nervous system developmentGO:004848410.1EDNRB, GDNF, RET
7response to painGO:00482659.9CALCA, EDNRB, RET
8neural crest cell migrationGO:00017559.9EDNRB, GDNF, RET
9vasodilationGO:00423119.7CALCA, EDNRB
10MAPK cascadeGO:00001659.7GDNF, GFRA1, MEN1, RET
11nervous system developmentGO:00073999.5EDNRB, GDNF, GFRA1, RET
12axon guidanceGO:00074119.2GDNF, GFRA1, RET, RYK

Molecular functions related to Multiple Endocrine Neoplasia Iib according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1Ras guanyl-nucleotide exchange factor activityGO:000508810.0GDNF, GFRA1, RET
2receptor bindingGO:00051028.7CALCA, GDNF, GFRA1, NCK1

Sources for Multiple Endocrine Neoplasia Iib

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet